Latest Updates in Lung Cancer
FDA Grants Traditional Approval to Tarlatamab-dlle for ES-SCLC After Phase 3 Survival Benefit
The FDA has granted full approval to Tarlatamab-dlle (Imdelltra) for patients with extensive-stage small-cell lung cancer progressing after platinum therapy....
AI Model Predicts EGFR Mutations from Pathology Slides in Real-Time Silent Trial for Lung Adenocarcinoma
AI can extract critical genetic insights directly from routine pathology slides, streamlining decisions and accelerating targeted therapy access.
FDA Approves First Maintenance Therapy for ES-SCLC: Lurbinectedin Plus Atezolizumab Extends Survival in IMforte Trial
FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6 months with atezolizumab alone (HR...
EMPOWER-Lung 1: Cemiplimab Shows Sustained 5-Year Survival Benefit in Advanced NSCLC
Five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy in advanced NSCLC patients with ≥50% PD-L1 expression.
Zipalertinib Demonstrates Activity in EGFR-Mutant NSCLC: Updated REZILIENT Trial Results from IASLC 2025
Zipalertinib demonstrated 27.4% response rate in EGFR ex20ins NSCLC patients post-amivantamab with 8.5-month duration of response.
Ideaya Advances Precision Oncology Pipeline with Positive Data from Three Cancer Drug Candidates
Ideaya presents promising data across three cancer drugs: darovasertib (76% response), IDE849 (58% response), and IDE397 combo (57% response).
Latest in Small Cell Lung Cancer (SCLC)
FDA Grants Traditional Approval to Tarlatamab-dlle for ES-SCLC After Phase 3 Survival Benefit
The FDA has granted full approval to Tarlatamab-dlle (Imdelltra) for patients with extensive-stage small-cell lung cancer progressing after platinum therapy....
FDA Approves First Maintenance Therapy for ES-SCLC: Lurbinectedin Plus Atezolizumab Extends Survival in IMforte Trial
FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6 months with atezolizumab alone (HR...
Ideaya Advances Precision Oncology Pipeline with Positive Data from Three Cancer Drug Candidates
Ideaya presents promising data across three cancer drugs: darovasertib (76% response), IDE849 (58% response), and IDE397 combo (57% response).
Histology Drives Lung Cancer Screening Effectiveness: Major Analysis of NELSON and NLST Trials
Screening effectiveness varies by histology, with adenocarcinoma showing 17.8-23.0% mortality reduction across trials.
DLL3 Trispecific Antibody Enhances T-Cell Infiltration in SCLC Through Novel CD3/CD137 Dual Targeting
Novel DLL3 trispecific antibody combines CD3 activation with CD137 costimulation to enhance T-cell infiltration in SCLC tumors.
FDA Grants Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
FDA grants breakthrough therapy designation to ifinatamab deruxtecan for pretreated extensive-stage small cell lung cancer patients.
Latest in Non-Small Cell Lung Cancer (NSCLC)
EMPOWER-Lung 1: Cemiplimab Shows Sustained 5-Year Survival Benefit in Advanced NSCLC
Five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy in advanced NSCLC patients with ≥50% PD-L1 expression.
Zipalertinib Demonstrates Activity in EGFR-Mutant NSCLC: Updated REZILIENT Trial Results from IASLC 2025
Zipalertinib demonstrated 27.4% response rate in EGFR ex20ins NSCLC patients post-amivantamab with 8.5-month duration of response.
ANKTIVA® Reverses Lymphopenia and Extends Survival in Checkpoint Inhibitor-Resistant NSCLC: Phase 2 Results Support Paradigm Shift
ANKTIVA reverses lymphopenia in 80% of checkpoint-resistant NSCLC patients, extending survival to 21.1 months in optimal responders.
FLAURA2 Final Analysis: Osimertinib Plus Chemotherapy Sets New Survival Standard in EGFR-Mutated Lung Cancer
Tagrisso plus chemo shows 47.5 months median OS vs 37.6 months monotherapy in EGFR+ lung cancer, setting new survival standard.
Overcoming Immune Checkpoint Inhibitor Resistance in NSCLC: A Review of Emerging Therapeutic Strategies
60-85% of NSCLC patients develop secondary resistance to ICIs, creating critical unmet need requiring novel immunotherapy strategies.
Histology Drives Lung Cancer Screening Effectiveness: Major Analysis of NELSON and NLST Trials
Screening effectiveness varies by histology, with adenocarcinoma showing 17.8-23.0% mortality reduction across trials.